Dr Reddy’s Laboratories anticipates a subdued performance for the December quarter. Pressure from its United States business is expected to offset steady growth in India and Europe. Analysts predict a decline in revenue and profit after tax. The US market faces challenges from pricing pressure and reduced contribution from gRevlimid.